Weave Bio provides an AI-native regulatory platform that transforms how life sciences companies prepare and manage complex dossiers across the therapeutic life cycle, reducing the time to get products into market.
Location: United States
Total raised: $30M
Investors 3
| Date | Name | Website |
| 10.07.2026 | US Venture... | usvp.com |
| 04.07.2025 | TMV | tmv.vc |
| 17.10.2025 | Character | character.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.10.2025 | Series A | $20M | Innovation... |
| 30.05.2024 | - | $10M | - |
Mentions in press and media 11
| Date | Title | Description |
| 01.09.2026 | Weave Bio and Takeda Deploy AI Regulatory Automation Across 14 Global Programs | What You Should Know AI-native regulatory software company Weave Bio announced a major enterprise collaboration with global biopharma leader Takeda to deploy its regulatory automation platform across 14 active drug development programs in m... |
| 29.04.2026 | Weave Bio Launches AI-Native NDA Submission Support in Strategic Partnership with Parexel | What You Should Know Weave Bio has expanded its AI-native regulatory platform to support New Drug Application (NDA) submissions, covering the full drug development lifecycle. Strategic partner Parexel co-developed and refined the platform, ... |
| 06.11.2025 | Weave Bio Launches HAQ Manager: AI Automation Accelerates Health Authority Question Responses | What You Should Know: – Weave Bio, the leader in AI-native regulatory automation, today announced the launch of HAQ Manager, a breakthrough capability that applies artificial intelligence (AI) and workflow automation to accelerate responses... |
| 18.10.2025 | Weave Bio Ignites AI Regulatory Revolution with $20M Funding | Weave Bio secured $20M in Series A funding, bringing total capital to $36M. This fuels its AI-native regulatory automation platform. It revolutionizes drug development, from lab to market. The investment targets global expansion, advanced A... |
| 17.10.2025 | Weave Bio Raises $20M in Series A Funding | Weave Bio, a San Francisco, CA-based provider of AI-native regulatory automation management solutions, raised $20m in Series A funding. The round, which brought total capital raised to $36m, was led by USVP, with participation by Innovation... |
| 17.10.2025 | Weave Bio: $20 Million Series A Closed For Expanding AI-Native Regulatory Platform For Global Drug Development | Weave Bio, a San Francisco-based company redefining regulatory automation through artificial intelligence, has raised $20 million in Series A funding, bringing its total capital raised to $36 million. The round was led by USVP, with additio... |
| 16.10.2025 | Weave Bio Raises $20M to Scale AI-Native Regulatory Automation Platform | What You Should Know: – Weave Bio, a pioneer in AI-native regulatory automation management solutions announced it has raised $20M in Series A funding, bringing the company’s total capital raised to $36M led by USVP, with participation from ... |
| 30.05.2024 | Weave Bio Launches for AI-Powered Drug Development, Secures $10M | What You Should Know: – Weave Bio, an AI-native life sciences platform company, announced today the public release of its flagship offering, AutoIND, and $10 million in seed funding co-led by Innovation Endeavors and Magnetic Ventures. – Au... |
| 30.05.2024 | Weave Bio Raises $10M in Funding | Weave Bio, a New Haven, CT-based provider of a AI-native life sciences platform, raised $10M in funding. The round was led by Innovation Endeavors and Magnetic Ventures. The company intends to use the funds to accelerate its pursuit of stre... |
| - | Weave | “Weave Bio is an AI-native regulatory automation platform streamlining submissions for novel therapies. Trusted by pharma, biotechs, and CROs, Weave automates drafting, integrates study data, and enhances efficiency—turning regulatory workf... |
Show more